CPT code 86803: Hepatitis C antibody test billing guide

Key Takeaways

CPT code 86803 describes a hepatitis C antibody test, qualitative or semiquantitative, used for HCV screening and diagnosis

The 2026 Medicare national non-facility reimbursement rate should be verified against the CMS Physician Fee Schedule; geographic adjusters apply by MAC locality

Bill ICD-10 Z11.59 for screening encounters and B18.2 for known chronic HCV; choosing the wrong pairing is a leading cause of denials

Pabau’s claims management software automates ICD-10 pairing and pre-submission scrubbing for lab codes, reducing denial rates for high-volume tests like 86803

CPT code 86803 is defined by the American Medical Association as: Hepatitis C antibody; qualitative or semiquantitative. It sits within the Immunology subsection of the Pathology and Laboratory chapter of the CPT code set. The test detects antibodies to the hepatitis C virus (HCV) in serum or plasma, confirming that a patient’s immune system has mounted a response to HCV exposure at some point in their history.

A few distinctions matter for accurate coding. “Qualitative” means the result is reported as reactive or non-reactive. “Semiquantitative” means a signal-to-cutoff ratio is reported alongside the qualitative interpretation, but this is not the same as a viral load measurement. CPT 86803 covers both test formats under a single descriptor. It does not cover HCV RNA quantitative testing, reflex PCR, or genotyping.

Clinical indications: When to order and bill CPT 86803

The U.S. Preventive Services Task Force (USPSTF) issued a Grade B recommendation in 2020 for HCV screening in all adults aged 18 to 79. That recommendation drives the majority of 86803 orders in primary care and infectious disease settings. Beyond the universal adult screening window, several clinical populations warrant testing regardless of age.

• Universal adult screening: Any patient aged 18-79 who has not previously been screened and has no documented prior HCV diagnosis
• High-risk populations: Patients with a history of injection drug use, blood transfusions before 1992, hemodialysis, HIV, or needlestick exposure
• Pregnancy: HCV screening is recommended during each pregnancy, regardless of prior results
• Symptomatic patients: Fatigue, elevated liver enzymes, jaundice, or right upper quadrant discomfort with no clear etiology
• Sexual health contexts: Sexual health clinics frequently order 86803 as part of STI screening panels for patients with elevated hepatitis exposure risk
• Follow-up after treatment: Post-direct-acting antiviral (DAA) monitoring typically requires HCV RNA, not 86803, but antibody testing may be ordered in surveillance protocols

Medical necessity documentation must link the order to one of these clinical scenarios. A bare order without a supporting ICD-10 code or documented indication is the most common reason payers deny 86803 claims.

Medicare reimbursement and fee schedule for CPT 86803 (2026)

Medicare reimburses 86803 under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. Rates are set nationally with no geographic adjustment for laboratory codes under CLFS. Always verify the current-year rate against the official CMS Physician Fee Schedule lookup tool and the CMS CLFS file before relying on any third-party source, as laboratory rates are finalized each November for the following year.

Submit 86803 claims through electronic claims via Claim.MD, Pabau’s integrated clearinghouse partner, which supports CMS-1500 and 837P claim formats across more than 4,000 US payers. Real-time eligibility verification before submission reduces preventable denials on Medicare HCV claims.

Relative value units (RVUs) for CPT 86803

CPT 86803 is a laboratory code. Its RVU structure reflects the reality of high-volume automated testing: work RVUs are low (or zero, as CMS assigns no physician work component to many lab codes), while practice expense RVUs carry the reimbursement weight.

Use the FastRVU 2026 RVU lookup or the CMS data file to retrieve current RVU components for this code.

ICD-10 codes commonly billed with CPT 86803

Correct ICD-10 selection is not optional for 86803 claims. Payers use diagnosis-to-procedure crosswalks to determine medical necessity, and mismatched pairs trigger automatic denials. The table below covers the most common pairings, but always confirm your payer’s current medical billing compliance policies before submitting.

CPT 86803 vs CPT 86804: Key differences

CPT 86804 describes a hepatitis C antibody confirmatory (supplemental) test. Where 86803 is the initial screening antibody immunoassay, 86804 covers additional antibody testing performed to confirm a reactive 86803 result before reflexing to HCV RNA. They are not interchangeable, and billing both together requires documentation that the confirmatory test was clinically indicated.

CPT 86803 vs HCPCS G0472: Which code to use for Medicare screening

This distinction confuses billers more than any other aspect of HCV coding. G0472 is a Medicare-specific HCPCS code covering hepatitis C screening for Medicare beneficiaries under the preventive benefit rules. CPT 86803 is the diagnostic lab code. Both describe an HCV antibody test at the laboratory bench, but the payer context, coverage pathway, and patient cost-sharing are fundamentally different.

Billing 86803 instead of G0472 for a Medicare screening encounter shifts the claim from preventive to diagnostic, triggering Part B cost-sharing for the patient. That is a compliance risk, not just an administrative error. Verify payer policy and encounter context before selecting between these two codes.

HCV reflex testing: when CPT 86803 is paired with HCV RNA

A reactive CPT 86803 result does not confirm active HCV infection. Antibodies persist for life after resolved infection, so a positive antibody screen must be followed by HCV RNA quantitative real-time PCR testing (typically billed under CPT 87522) to determine whether viremia is present. This reflex testing sequence is now standard of care per CDC and AASLD guidelines.

Understanding how to bill the full revenue cycle management workflow for reflex orders prevents the most common multi-code billing errors on HCV claims.

1. Order 86803 as the initial test with appropriate ICD-10 (Z11.59 for screening, or clinical indication code)
2. If reactive: order HCV RNA quantitative PCR (CPT 87522 or 87521) as a reflex; document the reactive 86803 result in the medical record
3. Bill both codes on the same claim date if performed same day, with the reflex order documented before submission
4. If 86804 also performed: include documentation of the confirmatory immunoassay step and why it preceded RNA testing
5. Confirm payer reflex policy: some MACs require prior authorization or specific modifier use for reflex panels billed on the same date of service

Review common denial codes in medical billing for reflex lab panels before setting up your billing workflow. Reflex orders denied for bundling or duplicate billing are among the most time-consuming to appeal.

Simplify lab billing and claim submission

Pabau integrates claim scrubbing, ICD-10 pairing, and clearinghouse submission in one workflow. See how practices reduce lab code denials without leaving their practice management system.

Book a demo

Billing guidelines and documentation requirements for CPT 86803

Getting paid for 86803 consistently requires documented medical necessity, correct code selection, and a clean claim on initial submission. The sections below cover the most common documentation and billing errors.

Documentation requirements

• Ordering provider documentation: The ordering provider must document the clinical indication for the test in the medical record. For screening orders, document patient age, absence of prior HCV screen, and reference to USPSTF guidance
• HIPAA-compliant records: Maintain HIPAA-compliant documentation for all lab orders and results, including the ordering provider’s NPI and the date of order
• Reflex orders: If reflex RNA testing is anticipated, document the reflex instruction in the original lab order; retroactive reflex orders are a common audit target
• Superbill accuracy: Ensure the superbill preparation process captures the correct ICD-10 code at the point of care, not at billing time

Common denial reasons and how to prevent them

• Wrong ICD-10: Using a diagnostic code (B18.2) for a screening encounter, or a screening code (Z11.59) for a symptomatic patient investigation – each signals a mismatch to the payer’s crosswalk logic
• Missing medical necessity: Claims submitted without a documented clinical indication or ordering note are returned as not medically necessary
• Frequency violations: Medicare and some commercial payers limit HCV antibody screening to once per lifetime for previously uninfected patients; repeated 86803 claims without a new clinical indication trigger edits
• Bundling errors: When 86803 and 86804 are billed together, payers expect documentation that the confirmatory test was ordered after a reactive initial result
• Place of service mismatch: Physician-office laboratory billing with a hospital place-of-service code, or vice versa, causes payment reduction or rejection

Proactive denial management workflows catch most of these errors before claims reach the payer. Track denial rates by CPT code monthly so high-volume lab codes like 86803 get early attention when patterns change.

How practice management software simplifies billing CPT 86803

High-volume lab codes create a specific billing risk: the faster a practice orders them, the more frequently the small errors compound. A biller manually selecting ICD-10 codes at claim time, without a crosswalk built into the workflow, makes the Z11.59 versus B18.2 mistake repeatedly. Practices that handle significant HCV testing volume need a system that removes that ambiguity at the point of order, not at the point of claim.

Pabau’s claims management software supports pre-submission scrubbing, helping teams identify ICD-10 pairing issues and documentation gaps before claims leave the practice. Combined with clearinghouse integration, eligibility verification, and electronic remittance advice reconciliation, the workflow closes the loop from lab order to paid claim in a single system.

Conclusion

CPT code 86803 is a straightforward descriptor with billing complexity that catches practices off guard. The code itself is simple. The challenge is selecting the right ICD-10 pairing, knowing when G0472 applies instead, managing reflex testing sequences, and keeping documentation tight enough to withstand payer scrutiny.

Pabau’s integrated claims management connects the lab order, the ICD-10 pairing, and the clearinghouse submission in one workflow, reducing the manual steps where 86803 denials most commonly originate. To see how it handles high-volume lab billing for your practice, book a demo with the Pabau team.

Continue your research

Need to understand how claims move from submission to payment? Medical billing fundamentals covers the full claim lifecycle for lab and clinical codes.

Getting ERA files back but unsure how to read them? Electronic remittance advice explained breaks down ERA components and how to reconcile payments.

Want to reduce denials before they happen? Clean claim best practices outlines the pre-submission checks that cut first-pass denial rates for lab codes.

Frequently Asked Questions